Alcoholic liver disease: Mechanisms of injury and targeted treatment

Nature Reviews Gastroenterology and Hepatology

Volumn 12, Issue 4, 2015, Pages 231-242

  Louvet, Alexandre ^a   Mathurin, Philippe ^a  

^a UNIVERSITÉ DE LILLE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; ALCOHOL; AMOXICILLIN PLUS CLAVULANIC ACID; ANTIOXIDANT; BASILIXIMAB; BETAINE; CIPROFLOXACIN; CORTICOSTEROID; EMRICASAN; ETANERCEPT; GARLIC ACID; INFLIXIMAB; METADOXIN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OBETICHOLIC ACID; PENTOXIFYLLINE; PLACEBO; PREDNISOLONE; PROBIOTIC AGENT; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RIFAXIMIN; RILONACEPT; S ADENOSYLMETHIONINE; TUMOR NECROSIS FACTOR ANTIBODY; TUMOR NECROSIS FACTOR INHIBITOR; UNCLASSIFIED DRUG; ZINC; CENTRAL DEPRESSANT AGENT;

ALCOHOL CONSUMPTION; ALCOHOL LIVER CIRRHOSIS; ALCOHOL LIVER DISEASE; ALCOHOL METABOLISM; ALCOHOLIC FATTY LIVER; COMBINATION CHEMOTHERAPY; CYTOTOXICITY; DISEASE COURSE; DRUG EFFECT; DRUG MECHANISM; DRUG RESPONSE; DRUG SENSITIVITY; DYSBIOSIS; FATTY LIVER; HUMAN; IMMUNITY; INSULIN RESISTANCE; LACTOBACILLUS RHAMNOSUS; LIVER CELL DAMAGE; LIVER REGENERATION; LONG TERM EXPOSURE; MONOTHERAPY; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; STEM CELL TRANSPLANTATION; ADVERSE EFFECTS; ANIMAL; DISEASE MODEL; DRINKING BEHAVIOR; LIVER; LIVER DISEASES, ALCOHOLIC; METABOLISM; PATHOLOGY;

ALCOHOL DRINKING; ANIMALS; CENTRAL NERVOUS SYSTEM DEPRESSANTS; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; ETHANOL; HUMANS; LIVER; LIVER DISEASES, ALCOHOLIC;

EID: 84926420371     PISSN: 17595045     EISSN: 17595053     Source Type: Journal    
DOI: 10.1038/nrgastro.2015.35     Document Type: Review

References (200)

1. European Association for the Study of the Liver. EASL clinical practical guidelines: management of alcoholic liver disease. J. Hepatol. 57, 399-420 (2012
2. Gao B. & Bataller R. Alcoholic liver disease: pathogenesis and new therapeutic targets. Gastroenterology 141, 1572-1585 (2011
3. Lucey M. R., Mathurin P. & Morgan T. R. Alcoholic hepatitis. N. Engl. J. Med. 360, 2758-2769 (2009
4. Mathurin P., et al. Fibrosis progression occurs in a subgroup of heavy drinkers with typical histological features. Aliment. Pharmacol. Ther. 25, 1047-1054 (2007
5. Pessione F., et al. Five-year survival predictive factors in patients with excessive alcohol intake and cirrhosis. Effect of alcoholic hepatitis smoking and abstinence. Liver Int. 23, 45-53 (2003
6. Verrill C., Markham H., Templeton A., Carr N. J. & Sheron N. Alcohol-related cirrhosis-early abstinence is a key factor in prognosis even in the most severe cases. Addiction 104, 768-774 (2009
7. Mendenhall C. L. Anabolic steroid therapy as an adjunct to diet in alcoholic hepatic steatosis. Am. J. Dig. Dis. 13, 783-791 (1968
8. Galambos J. T. Natural history of alcoholic hepatitis. 3. Histological changes. Gastroenterology 63, 1026-1035 (1972
9. Pares A., Caballeria J., Bruguera M., Torres M. & Rodes J. Histological course of alcoholic hepatitis. Influence of abstinence sex and extent of hepatic damage. J. Hepatol. 2, 33-42 (1986
10. Norberg A., Jones A. W., Hahn R. G. & Gabrielsson J. L. Role of variability in explaining ethanol pharmacokinetics: research and forensic applications. Clin. Pharmacokinet. 42, 1-31 (2003
11. Cederbaum A. I. Alcohol metabolism. Clin. Liver Dis. 16, 667-685 (2012
12. Lieber C. S. ALCOHOL: its metabolism and interaction with nutrients. Ann. Rev. Nutr. 20, 395-430 (2000
13. Lieber C. S. Alcoholic fatty liver: its pathogenesis and mechanism of progression to inflammation and fibrosis. Alcohol 34, 9-19 (2004
14. Lu Y. & Cederbaum A. I. CYP2E1 and oxidative liver injury by alcohol. Free Radic. Biol. Med. 44, 723-738 (2008
15. Lieber C. S. Microsomal ethanol-oxidizing system (MEOS): the first 30 years (1968-1998)-a review. Alcohol. Clin. Exp. Res. 23, 991-1007 (1999
16. Cederbaum A. I. Cytochrome P450 2E1-dependent oxidant stress and upregulation of anti-oxidant defense in liver cells. J. Gastroenterol. Hepatol. 21 (Suppl. 3), S22-S25 (2006
17. Wheeler M. D., et al. The role of Kupffer cell oxidant production in early ethanol-induced liver disease. Free Radic. Biol. Med. 31, 1544-1549 (2001
18. Philippe M. A., Ruddell R. G. & Ramm G. A. Role of iron in hepatic fibrosis: one piece in the puzzle. World J. Gastroenterol. 13, 4746-4754 (2007
19. Tsukamoto H., et al. Experimental liver cirrhosis induced by alcohol and iron. J. Clin. Invest. 96, 620-630 (1995
20. Luedde T., Kaplowitz N. & Schwabe R. F. Cell death and cell death responses in liver disease: mechanisms and clinical relevance. Gastroenterology 147, 765-783 (2014
21. Brenner C., Galluzzi L., Kepp O. & Kroemer G. Decoding cell death signals in liver inflammation. J. Hepatol. 59, 583-594 (2013
22. Dolganiuc A., Thomes P. G., Ding W. X., Lemasters J. J. & Donohue T. M. Jr. Autophagy in alcohol-induced liver diseases. Alcohol. Clin. Exp. Res. 36, 1301-1308 (2012
23. Fernandez-Checa J. C., Garcia-Ruiz C., Ookhtens M. & Kaplowitz N. Impaired uptake of glutathione by hepatic mitochondria from chronic ethanol-fed rats. Tracer kinetic studies in vitro and in vivo and susceptibility to oxidant stress. J. Clin. Invest. 87, 397-405 (1991
24. Fernandez-Checa J. C., Ookhtens M. & Kaplowitz N. Effects of chronic ethanol feeding on rat hepatocytic glutathione. Relationship of cytosolic glutathione to efflux and mitochondrial sequestration. J. Clin. Invest. 83, 1247-1252 (1989
25. Hirano T., Kaplowitz N., Tsukamoto H., Kamimura S. & Fernandez-Checa J. C. Hepatic mitochondrial glutathione depletion and progression of experimental alcoholic liver disease in rats. Hepatology 16, 1423-1427 (1992
26. Wheeler M. D., et al. Overexpression of manganese superoxide dismutase prevents alcohol-induced liver injury in the rat. J. Biol. Chem. 276, 36664-36672 (2001
27. Fernandez-Checa J. C., Kaplowitz N., Garcia Ruiz C. & Colell A. Mitochondrial glutathione: importance and transport. Semin. Liver Dis. 18, 389-401 (1998
28. Fernandez-Checa J. C., Hirano T., Tsukamoto H. & Kaplowitz N. Mitochondrial glutathione depletion in alcoholic liver disease. Alcohol 10, 469-475 (1993
29. Gong P., Cederbaum A. I. & Nieto N. Heme oxygenase 1 protects HepG2 cells against cytochrome P450 2E1-dependent toxicity. Free Radic. Biol. Med. 36, 307-318 (2004
30. Imrie D. & Sadler K. C. Stress management: how the unfolded protein response impacts fatty liver disease. J. Hepatol. 57, 1147-1151 (2012
31. Malhi H. & Kaufman R. J. Endoplasmic reticulum stress in liver disease. J. Hepatol. 54, 795-809 (2011
32. Ji C., Deng Q. & Kaplowitz N. Role of TNF-α in ethanol-induced hyperhomocysteinemia and murine alcoholic liver injury. Hepatology 40, 442-451 (2004
33. Petrasek J., et al. STING-IRF3 pathway links endoplasmic reticulum stress with hepatocyte apoptosis in early alcoholic liver disease. Proc. Natl Acad. Sci. USA 110, 16544-16549 (2013
34. Esfandiari F., Villanueva J. A., Wong D. H., French S. W. & Halsted C. H. Chronic ethanol feeding and folate deficiency activate hepatic endoplasmic reticulum stress pathway in micropigs. Am. J. Physiol. 289, G54-G63 (2005
35. Ji C. Dissection of endoplasmic reticulum stress signaling in alcoholic and non-alcoholic liver injury. J. Gastroenterol. Hepatol. 23 (Suppl. 1), S16-S24 (2008
36. Crabb D. W. & Liangpunsakul S. Alcohol and lipid metabolism. J. Gastroenterol. Hepatol. 21 (Suppl. 3), S56-S60 (2006
37. Ji C. & Kaplowitz N. Betaine decreases hyperhomocysteinemia endoplasmic reticulum stress and liver injury in alcohol-fed mice. Gastroenterology 124, 1488-1499 (2003
38. Hernandez-Gea V., et al. Endoplasmic reticulum stress induces fibrogenic activity in hepatic stellate cells through autophagy. J. Hepatol. 59, 98-104 (2013
39. You M., Fischer M., Deeg M. A. & Crabb D. W. Ethanol induces fatty acid synthesis pathways by activation of sterol regulatory element-binding protein (SREBP). J. Biol. Chem. 277, 29342-29347 (2002
40. Endo M., Masaki T., Seike M. & Yoshimatsu H. TNF-α induces hepatic steatosis in mice by enhancing gene expression of sterol regulatory element binding protein-1c (SREBP-1c). Exp. Biol. Med (Maywood) 232, 614-621 (2007
41. Lawler J. F. Jr Yin M., Diehl A. M., Roberts E. & Chatterjee S. Tumor necrosis factor-α stimulates the maturation of sterol regulatory element binding protein 1 in human hepatocytes through the action of neutral sphingomyelinase. J. Biol. Chem. 273, 5053-5059 (1998
42. Nakajima T., et al. Peroxisome proliferator-activated receptor alpha protects against alcohol-induced liver damage. Hepatology 40, 972-980 (2004
43. Galli A., Pinaire J., Fischer M., Dorris R. & Crabb D. W. The transcriptional and DNA binding activity of peroxisome proliferator-activated receptor α is inhibited by ethanol metabolism. A novel mechanism for the development of ethanol-induced fatty liver. J. Biol. Chem. 276, 68-75 (2001
44. Fischer M., You M., Matsumoto M. & Crabb D. W. Peroxisome proliferator-activated receptor alpha (PPARalpha) agonist treatment reverses PPARalpha dysfunction and abnormalities in hepatic lipid metabolism in ethanol-fed mice. J. Biol. Chem. 278, 27997-28004 (2003
45. Molina P. E. Alcohol-intoxicating roadblocks and bottlenecks in hepatic protein and lipid metabolism. Am. J. Physiol. Endocrinol. Metab. 295, E1-E2 (2008
46. Zhou G., et al. Role of AMP-activated protein kinase in mechanism of metformin action. J. Clin. Invest. 108, 1167-1174 (2001
47. Garcia-Villafranca J., Guillen A. & Castro J. Ethanol consumption impairs regulation of fatty acid metabolism by decreasing the activity of AMP-activated protein kinase in rat liver. Biochimie 90, 460-466 (2008
48. You M. & Crabb D. W. Recent advances in alcoholic liver disease. I. Minireview: molecular mechanisms of alcoholic fatty liver. Am. J. Physiol. 287, G1-G6 (2004
49. Yin H., et al. Deletion of SIRT1 from hepatocytes in mice disrupts lipin 1 signaling and aggravates alcoholic fatty liver. Gastroenterology 146, 801-811 (2014
50. You M., Liang X., Ajmo J. M. & Ness G. C. Involvement of mammalian sirtuin 1 in the action of ethanol in the liver. Am. J. Physiol. 294, G892-G898 (2008
51. Jeong W. I., et al. Paracrine activation of hepatic CB1 receptors by stellate cell-derived endocannabinoids mediates alcoholic fatty liver. Cell. Metab. 7, 227-235 (2008
52. Louvet A., et al. Cannabinoid CB2 receptors protect against alcoholic liver disease by regulating Kupffer cell polarization in mice. Hepatology 54, 1217-1226 (2011
53. Bykov I., et al. Hepatic gene expression and lipid parameters in complement C3-/- mice that do not develop ethanol-induced steatosis. J. Hepatol. 46, 907-914 (2007
54. Cohen J. I., Roychowdhury S., McMullen M. R., Stavitsky A. B. & Nagy L. E. Complement and alcoholic liver disease: role of C1q in the pathogenesis of ethanol-induced liver injury in mice. Gastroenterology 139, 664-674. (2010
55. Pritchard M. T., et al. Differential contributions of C3, C5, and decay-accelerating factor to ethanol-induced fatty liver in mice. Gastroenterology 132, 1117-1126 (2007
56. Tomita K., et al. Pioglitazone prevents alcohol-induced fatty liver in rats through up-regulation of c Met. Gastroenterology 126, 873-885 (2004
57. Naveau S., et al. Harmful effect of adipose tissue on liver lesions in patients with alcoholic liver disease. J. Hepatol. 52, 895-902 (2010
58. Naveau S. Excess weight risk factor for alcoholic liver disease. Hepatology 25, 108-111 (1997
59. Raynard B., et al. Risk factors of fibrosis in alcohol-induced liver disease. Hepatology 35, 635-638 (2002
60. Dunn W., et al. Modest alcohol consumption is associated with decreased prevalence of steatohepatitis in patients with non-alcoholic fatty liver disease (NAFLD). J. Hepatol. 57, 384-391 (2012
61. Kang L., et al. Chronic ethanol-induced insulin resistance is associated with macrophage infiltration into adipose tissue and altered expression of adipocytokines. Alcohol. Clin. Exp. Res. 31, 1581-1588 (2007
62. Xu A., et al. The fat-derived hormone adiponectin alleviates alcoholic and nonalcoholic fatty liver diseases in mice. J. Clin. Invest. 112, 91-100 (2003
63. Yamauchi T., et al. Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nat. Med. 8, 1288-1295 (2002
64. You M., Considine R. V., Leone T. C., Kelly D. P. & Crabb D. W. Role of adiponectin in the protective action of dietary saturated fat against alcoholic fatty liver in mice. Hepatology 42, 568-577 (2005
65. Song Z., Zhou Z., Deaciuc I., Chen T. & McClain C. J. Inhibition of adiponectin production by homocysteine: a potential mechanism for alcoholic liver disease. Hepatology 47, 867-879 (2008
66. Mathurin P., et al. Exacerbation of alcoholic liver injury by enteral endotoxin in rats. Hepatology 32, 1008-1017 (2000
67. Parlesak A., Schafer C., Schutz T., Bode J. C. & Bode C. Increased intestinal permeability to macromolecules and endotoxemia in patients with chronic alcohol abuse in different stages of alcohol-induced liver disease. J. Hepatol. 32, 742-747 (2000
68. Tamai H., Horie Y., Kato S., Yokoyama H. & Ishii H. Long-term ethanol feeding enhances susceptibility of the liver to orally administered lipopolysaccharides in rats. Alcohol. Clin. Exp. Res. 26 (8 Suppl.) 75S-80S (2002
69. Fujimoto M., et al. Plasma endotoxin and serum cytokine levels in patients with alcoholic hepatitis: relation to severity of liver disturbance. Alcohol. Clin. Exp. Res. 24 (4 Suppl.) 48S-54S (2000
70. Hanck C., Rossol S., Bocker U., Tokus M., Singer M. V. Presence of plasma endotoxin is correlated with tumour necrosis factor receptor levels and disease activity in alcoholic cirrhosis. Alcohol Alcohol. 33, 606-608 (1998
71. Bhagwandeen B. S., Apte M., Manwarring L. & Dickeson J. Endotoxin induced hepatic necrosis in rats on an alcohol diet. J. Pathol. 152, 47-53 (1987
72. Adachi Y., Moore L. E., Bradford B. U., Gao W. & Thurman R. G. Antibiotics prevent liver injury in rats following long-term exposure to ethanol. Gastroenterology 108, 218-224 (1995
73. Nanji A. A., Khettry U. & Sadrzadeh S. M. Lactobacillus feeding reduces endotoxemia and severity of experimental alcoholic liver (disease). Proc. Soc. Exp. Biol Med. 205, 243-247 (1994
74. Gustot T., et al. Differential liver sensitization to toll-like receptor pathways in mice with alcoholic fatty liver. Hepatology 43, 989-1000 (2006
75. Oak S., Mandrekar P., Catalano D., Kodys K. & Szabo G. TLR2- and TLR4-mediated signals determine attenuation or augmentation of inflammation by acute alcohol in monocytes. J. Immunol. 176, 7628-7635 (2006
76. Guha M. & Mackman N. LPS induction of gene expression in human monocytes. Cell. Signal. 13, 85-94 (2001
77. Wheeler M. D. & Thurman R. G. Up-regulation of CD14 in liver caused by acute ethanol involves oxidant-dependent AP 1 pathway. J. Biol. Chem. 278, 8435-8441 (2003
78. Hritz I., et al. The critical role of toll-like receptor (TLR) 4 in alcoholic liver disease is independent of the common TLR adapter MyD88. Hepatology 48, 1224-1231 (2008
79. Zima T. & Kalousova M. Oxidative stress and signal transduction pathways in alcoholic liver disease. Alcohol. Clin. Exp. Res. 29 (11 Suppl.) 110S-115S (2005
80. De Minicis S. & Brenner D. A. Oxidative stress in alcoholic liver disease: role of NADPH oxidase complex. J. Gastroenterol. Hepatol. 23 (Suppl. 1) S98-S103 (2008
81. Uesugi T., Froh M., Arteel G. E., Bradford B. U. & Thurman R. G. Toll-like receptor 4 is involved in the mechanism of early alcohol-induced liver injury in mice. Hepatology 34, 101-108 (2001
82. Xiong S., et al. Hepatic macrophage iron aggravates experimental alcoholic steatohepatitis. Am. J. Physiol. 295, G512-G521 (2008
83. Lin M., Rippe R. A., Niemela O., Brittenham G. & Tsukamoto H. Role of iron in NF kappa B activation and cytokine gene expression by rat hepatic macrophages. Am. J. Physiol. 272, G1355-G1364 (1997
84. She H., et al. Iron activates NF kappaB in Kupffer cells. Am. J. Physiol. 283, G719-G726 (2002
85. Tsukamoto H., et al. Iron primes hepatic macrophages for NF kappaB activation in alcoholic liver injury. Am. J. Physiol. 277, G1240-G1250 (1999
86. Afford S. C., et al. Distinct patterns of chemokine expression are associated with leukocyte recruitment in alcoholic hepatitis and alcoholic cirrhosis. J. Pathol. 186, 82-89 (1998
87. Colmenero J., et al. Hepatic expression of candidate genes in patients with alcoholic hepatitis: correlation with disease severity. Gastroenterology 132, 687-697 (2007
88. Maltby J., Wright S., Bird G. & Sheron N. Chemokine levels in human liver homogenates: associations between GRO alpha and histopathological evidence of alcoholic hepatitis. Hepatology 24, 1156-1160 (1996
89. Taieb J., et al. Blood neutrophil functions and cytokine release in severe alcoholic hepatitis: effect of corticosteroids. J. Hepatol. 32, 579-586 (2000
90. Barnes M. A., et al. Macrophage migration inhibitory factor contributes to ethanol-induced liver injury by mediating cell injury steatohepatitis and steatosis. Hepatology 57, 1980-1991 (2013
91. Mandrekar P., Ambade A., Lim A., Szabo G. & Catalano D. An essential role for monocyte chemoattractant protein 1 in alcoholic liver injury: regulation of proinflammatory cytokines and hepatic steatosis in mice. Hepatology 54, 2185-2197 (2011
92. Wan J., et al. M2 Kupffer cells promote M1 Kupffer cell apoptosis: a protective mechanism against alcoholic and nonalcoholic fatty liver disease. Hepatology 59, 130-142 (2014
93. Byun J. S., Suh Y. G., Yi H. S., Lee Y. S. & Jeong W. I. Activation of Toll-like receptor 3 attenuates alcoholic liver injury by stimulating Kupffer cells and stellate cells to produce interleukin 10 in mice. J. Hepatol. 58, 342-349 (2013
94. Minagawa M., Deng Q., Liu Z. X., Tsukamoto H. & Dennert G. Activated natural killer T cells induce liver injury by Fas and tumor necrosis factor-alpha during alcohol consumption. Gastroenterology 126, 1387-1399 (2004
95. Szabo G. & Mandrekar P. A recent perspective on alcohol immunity and host defense. Alcohol. Clin. Exp. Res. 33, 220-232 (2009
96. Brun P., Castagliuolo I., Pinzani M., Palu G. & Martines D. Exposure to bacterial cell wall products triggers an inflammatory phenotype in hepatic stellate cells. Am. J. Physiol. 289, G571-G578 (2005
97. Paik Y. H., et al. Toll-like receptor 4 mediates inflammatory signaling by bacterial lipopolysaccharide in human hepatic stellate cells. Hepatology 37, 1043-1055 (2003
98. Thirunavukkarasu C., Uemura T., Wang L. F., Watkins S. C. & Gandhi C. R. Normal rat hepatic stellate cells respond to endotoxin in LBP-independent manner to produce inhibitor(s) of DNA synthesis in hepatocytes. J. Cell. Physiol. 204, 654-665 (2005
99. Yan A. W., et al. Enteric dysbiosis associated with a mouse model of alcoholic liver disease. Hepatology 53, 96-105 (2011
100. Mutlu E., et al. Intestinal dysbiosis: a possible mechanism of alcohol-induced endotoxemia and alcoholic steatohepatitis in rats. Alcohol. Clin. Exp. Res. 33, 1836-1846 (2009
101. Chen P., Starkel P., Turner J. R., Ho S. B. & Schnabl B. Dysbiosis-induced intestinal inflammation activates tumor necrosis factor I and mediates alcoholic liver disease in mice. Hepatology http://dx.doi.org/10.1002/hep.27489
102. Schnabl B. & Brenner D. A. Interactions between the intestinal microbiome and liver diseases. Gastroenterology 146, 1513-1524 (2014
103. Chen P., et al. Supplementation of saturated long-chain fatty acids maintains intestinal eubiosis and reduces ethanol-induced liver injury in mice. Gastroenterology 148, 203-214 (2014
104. Mutlu E. A., et al. Colonic microbiome is altered in alcoholism. Am. J. Physiol. 302, G966-G978 (2012
105. Qin N., et al. Alterations of the human gut microbiome in liver cirrhosis. Nature 513, 59-64 (2014
106. Forsyth C. B., et al. Lactobacillus GG treatment ameliorates alcohol-induced intestinal oxidative stress gut leakiness and liver injury in a rat model of alcoholic steatohepatitis. Alcohol 43, 163-172 (2009
107. Stadlbauer V., et al. Effect of probiotic treatment on deranged neutrophil function and cytokine responses in patients with compensated alcoholic cirrhosis. J. Hepatol. 48, 945-951 (2008
108. Kirpich I. A., et al. Probiotics restore bowel flora and improve liver enzymes in human alcohol-induced liver injury: a pilot study. Alcohol 42, 675-682 (2008
109. Delzenne N. M., Neyrinck A. M., Backhed F. & Cani P. D. Targeting gut microbiota in obesity: effects of prebiotics and probiotics. Nat. Rev. Endocrinol. 7, 639-646 (2011
110. Malaguarnera G., Giordano M., Nunnari G., Bertino G. & Malaguarnera M. Gut microbiota in alcoholic liver disease: pathogenetic role and therapeutic perspectives. World J. Gastroenterol. 20, 16639-16648 (2014
111. Diehl A. M. Recent events in alcoholic liver disease V. effects of ethanol on liver regeneration. Am. J. Physiol. 288, G1-G6 (2005
112. Michalopoulos G. K. Liver regeneration: alternative epithelial pathways. Int. J. Biochem. Cell Biol. 43, 173-179 (2011
113. Cosgrove B. D., et al. An inducible autocrine cascade regulates rat hepatocyte proliferation and apoptosis responses to tumor necrosis factor-alpha. Hepatology 48, 276-288 (2008
114. Freimuth J., et al. Loss of caspase 8 in hepatocytes accelerates the onset of liver regeneration in mice through premature nuclear factor kappa B activation. Hepatology 58, 1779-1789 (2013
115. Wang H., et al. Interplay of hepatic and myeloid signal transducer and activator of transcription 3 in facilitating liver regeneration via tempering innate immunity. Hepatology 51, 1354-1362 (2010
116. Webber E. M., Bruix J., Pierce R. H. & Fausto N. Tumor necrosis factor primes hepatocytes for DNA replication in the rat. Hepatology 28, 1226-1234 (1998
117. Xu M. J., et al. Liver is the major source of elevated serum lipocalin 2 levels after bacterial infection or partial hepatectomy: a critical role for IL 6/STAT3. Hepatology 61, 692-702 (2015
118. Roskams T., et al. Oxidative stress and oval cell accumulation in mice and humans with alcoholic and nonalcoholic fatty liver disease. Am. J. Physiol. 163, 1301-1311 (2003
119. Koteish A., Yang S., Lin H., Huang X. & Diehl A. M. Chronic ethanol exposure potentiates lipopolysaccharide liver injury despite inhibiting Jun N terminal kinase and caspase 3 activation. J. Biol. Chem. 277, 13037-13044 (2002
120. Dippold R. P., Vadigepalli R., Gonye G. E., Patra B. & Hoek J. B. Chronic ethanol feeding alters miRNA expression dynamics during liver regeneration. Alcohol. Clin. Exp. Res. 37 (Suppl. 1) E59-E69 (2013
121. Jung Y., et al. Accumulation of hedgehog-responsive progenitors parallels alcoholic liver disease severity in mice and humans. Gastroenterology 134, 1532-1543 (2008
122. Sancho-Bru P., et al. Liver progenitor cell markers correlate with liver damage and predict short-term mortality in patients with alcoholic hepatitis. Hepatology 55, 1931-1941 (2012
123. Dubuquoy L., et al. Progenitor cell expansion and impaired hepatocyte regeneration in explanted livers from alcoholic hepatitis. Gut (in press
124. Tsuchiya M., et al. Interstrain differences in liver injury and one-carbon metabolism in alcohol-fed mice. Hepatology 56, 130-139 (2012
125. Lieber C. S., Jones D. P. & Decarli L. M. Effects of prolonged ethanol intake: production of fatty liver despite adequate diets. J. Clin. Invest. 44, 1009-1021 (1965
126. Lieber C. S., DeCarli L. M. & Sorrell M. F. Experimental methods of ethanol administration. Hepatology 10, 501-510 (1989
127. Tsukamoto H., et al. Severe and progressive steatosis and focal necrosis in rat liver induced by continuous intragastric infusion of ethanol and low fat diet. Hepatology 5, 224-232 (1985
128. Tsukamoto H., Reidelberger R. D., French S. W. & Largman C. Long-term cannulation model for blood sampling and intragastric infusion in the rat. Am. J. Physiol. 247, R595-R599 (1984
129. von Montfort C., Beier J. I., Guo L., Kaiser J. P. & Arteel G. E. Contribution of the sympathetic hormone epinephrine to the sensitizing effect of ethanol on LPS-induced liver damage in mice. Am. J. Physiol. 294, G1227-G1234 (2008
130. Bertola A., Park O. & Gao B. Chronic plus binge ethanol feeding synergistically induces neutrophil infiltration and liver injury in mice: a critical role for E selectin. Hepatology 58, 1814-1823 (2013
131. Mathews S., Xu M., Wang H., Bertola A. & Gao B. Animals models of gastrointestinal and liver diseases. Animal models of alcohol-induced liver disease: pathophysiology translational relevance and challenges. Am. J. Physiol. 306, G819-G823 (2014
132. Affo S., et al. Transcriptome analysis identifies TNF superfamily receptors as potential therapeutic targets in alcoholic hepatitis. Gut 62, 452-460 (2013
133. Altamirano J., et al. A histologic scoring system for prognosis of patients with alcoholic hepatitis. Gastroenterology 146, 1231-1239 (2014
134. Affo S., et al. CCL20 mediates lipopolysaccharide induced liver injury and is a potential driver of inflammation and fibrosis in alcoholic hepatitis. Gut 63, 1782-1792 (2014
135. Dominguez M., et al. Hepatic expression of CXC chemokines predicts portal hypertension and survival in patients with alcoholic hepatitis. Gastroenterology 136, 1639-1650 (2009
136. Morales-Ibanez O., et al. Human and experimental evidence supporting a role for osteopontin in alcoholic hepatitis. Hepatology 58, 1742-1756 (2013
137. Yong K. J., et al. Oncofetal gene SALL4 in aggressive hepatocellular carcinoma. N. Engl. J. Med. 368, 2266-2276 (2013
138. O'shea R. S., Dasarathy S. & McCullough A. J. Alcoholic liver disease. Am. J. Gastroenterol. 105, 14-32 (2010
139. Mathurin P., et al. Corticosteroids improve short-term survival in patients with severe alcoholic hepatitis (AH): individual data analysis of the last three randomized placebo controlled double blind trials of corticosteroids in severe AH. J. Hepatol. 36, 480-487 (2002
140. Mathurin P., et al. Corticosteroids improve short-term survival in patients with severe alcoholic hepatitis: meta-analysis of individual patient data. Gut 60, 255-260 (2011
141. Forrest E. H., et al. Analysis of factors predictive of mortality in alcoholic hepatitis and derivation and validation of the Glasgow alcoholic hepatitis score. Gut 54, 1174-1179 (2005
142. Dominguez M., et al. A new scoring system for prognostic stratification of patients with alcoholic hepatitis. Am. J. Gastroenterol. 103, 2747-2756 (2008
143. Louvet A., et al. The Lille model: a new tool for therapeutic strategy in patients with severe alcoholic hepatitis treated with steroids. Hepatology 45, 1348-1354 (2007
144. Centre Hospitalier Regional Universitaire de Lille. Lille Model. LilleModel.com [online], http://www.lillemodel.com/(2015
145. Mathurin P., et al. Early change in bilirubin levels is an important prognostic factor in severe alcoholic hepatitis treated with prednisolone. Hepatology 38, 1363-1369 (2003
146. Iimuro Y., Gallucci R. M., Luster M. I., Kono H. & Thurman R. G. Antibodies to tumor necrosis factor alfa attenuate hepatic necrosis and inflammation caused by chronic exposure to ethanol in the rat. Hepatology 26, 1530-1537 (1997
147. Yin M., et al. Essential role of tumor necrosis factor alpha in alcohol-induced liver injury in mice. Gastroenterology 117, 942-952 (1999
148. Naveau S., et al. Plasma levels of soluble tumor necrosis factor receptors p55 and p75 in patients with alcoholic liver disease of increasing severity. J. Hepatol. 28, 778-784 (1998
149. Spahr L., et al. Soluble TNF R1, but not tumor necrosis factor alpha predicts the 3 month mortality in patients with alcoholic hepatitis. J. Hepatol. 41, 229-234 (2004
150. Kendrick S. F., Henderson E., Palmer J., Jones D. E. & Day C. P. Theophylline improves steroid sensitivity in acute alcoholic hepatitis. Hepatology 52, 126-131 (2010
151. di Mambro A. J., et al. In vitro steroid resistance correlates with outcome in severe alcoholic hepatitis. Hepatology 53, 1316-1322 (2011
152. Dhanda A. D., et al. Long-term outcome in patients with severe alcoholic hepatitis can be reliably determined using an in vitro measure of steroid sensitivity. Hepatology http://dx.doi.org/10.1002/hep.27211
153. Kendrick S. F., et al. Acetate the key modulator of inflammatory responses in acute alcoholic hepatitis. Hepatology 51, 1988-1997 (2010
154. Hamdi H., et al. Glucocorticoid-induced leucine zipper: A key protein in the sensitization of monocytes to lipopolysaccharide in alcoholic hepatitis. Hepatology 46, 1986-1992 (2007
155. Mookerjee R. P., et al. Tumour necrosis factor alpha is an important mediator of portal and systemic haemodynamic derangements in alcoholic hepatitis. Gut 52, 1182-1187 (2003
156. Spahr L., et al. Combination of steroids with infliximab or placebo in severe alcoholic hepatitis: a randomized controlled pilot study. J. Hepatol. 37, 448-455 (2002
157. Tilg H., et al. Anti-tumor necrosis factor-alpha monoclonal antibody therapy in severe alcoholic hepatitis. J. Hepatol. 38, 419-425 (2003
158. Sharma P., Kumar A., Sharma B. C. & Sarin S. K. Infliximab monotherapy for severe alcoholic hepatitis and predictors of survival: an open label trial. J. Hepatol. 50, 584-591 (2009
159. Naveau S., et al. A double-blind randomized controlled trial of infliximab associated with prednisolone in acute alcoholic hepatitis. Hepatology 39, 1390-1397 (2004
160. Boetticher N. C., et al. A randomized double-blinded placebo-controlled multicenter trial of etanercept in the treatment of alcoholic hepatitis. Gastroenterology 135, 1953-1960 (2008
161. Brenndorfer E. D., et al. Anti-tumor necrosis factor alpha treatment promotes apoptosis and prevents liver regeneration in a transgenic mouse model of chronic hepatitis C. Hepatology 52, 1553-1563 (2010
162. Akriviadis E., et al. Pentoxifylline improves short term survival in severe acute alcoholic hepatitis: a double-blind placebo-controlled trial. Gastroenterology 119, 1637-1648 (2000
163. Sidhu S. S., et al. Corticosteroid plus pentoxifylline is not better than corticosteroid alone for improving survival in severe alcoholic hepatitis (COPE trial). Dig. Dis. Sci. 57, 1664-1671 (2012
164. De B. K., et al. Pentoxifylline versus prednisolone for severe alcoholic hepatitis: a randomized controlled trial. World J. Gastroenterol. 15, 1613-1619 (2009
165. Doherty G. M., Jensen J. C., Alexander H. R., Buresh C. M. & Norton J. A. Pentoxifylline suppression of tumor necrosis factor gene transcription. Surgery 110, 192-198 (1991
166. Han J., Thompson P. & Beutler B. Dexamethasone and pentoxifylline inhibit endotoxin-induced cachectin/tumor necrosis factor synthesis at separate points in the signaling pathway. J. Exp. Med. 172, 391-394 (1990
167. Louvet A., et al. Early switch to pentoxifylline in patients with severe alcoholic hepatitis is inefficient in non-responders to corticosteroids. J. Hepatol. 48, 465-470 (2008
168. Mathurin P., et al. Prednisolone with vs without pentoxifylline and survival of patients with severe alcoholic hepatitis: a randomized clinical trial. JAMA 310, 1033-1041 (2013
169. Park S. H., et al. Pentoxifylline vs. corticosteroid to treat severe alcoholic hepatitis: a randomised non-inferiority open trial. J. Hepatol. 61, 792-798 (2014
170. Thursz M., et al. Steroids or Pentoxifylline for Alcoholic Hepatitis: Results of the STOPAH Trial. Hepatology 60, LB1 (2014
171. Lebrec D., et al. Pentoxifylline does not decrease short-term mortality but does reduce complications in patients with advanced cirrhosis. Gastroenterology 138, 1755-1762 (2010
172. Lieber C. S. S Adenosyl l-methionine and alcoholic liver disease in animal models: implications for early intervention in human beings. Alcohol 27, 173-177 (2002
173. Colell A., et al. Transport of reduced glutathione in hepatic mitochondria and mitoplasts from ethanol-treated rats: effect of membrane physical properties and S adenosyl l-methionine. Hepatology 26, 699-708 (1997
174. Garcia-Ruiz C. Effect of chronic ethanol feeding on glutathione and functional integrity of mitochondria in periportal and perivenous rat hepatocytes. J. Clin. Invest. 94, 193-201 (1994
175. Phillips M., et al. Antioxidants versus corticosteroids in the treatment of severe alcoholic hepatitis- a randomised clinical trial. J. Hepatol. 44, 784-790 (2006
176. Moreno C., et al. Enteral nutrition with or without N acetylcysteine in the treatment of severe acute alcoholic hepatitis: a randomized multicenter controlled trial. J. Hepatol. 53, 1117-1122 (2010
177. Stewart S., et al. A randomized trial of antioxidant therapy alone or with corticosteroids in acute alcoholic hepatitis. J. Hepatol. 47, 277-283 (2007
178. Nguyen-Khac E., et al. Glucocorticoids plus N acetylcysteine in severe alcoholic hepatitis. N. Engl. J. Med. 365, 1781-1789 (2011
179. Gustot T., Durand F., Lebrec D., Vincent J. L. & Moreau R. Severe sepsis in cirrhosis. Hepatology 50, 2022-2033 (2009
180. Louvet A., et al. Infection in patients with severe alcoholic hepatitis treated with steroids: early response to therapy is the key factor. Gastroenterology 137, 541-548 (2009
181. Wasmuth H. E., et al. Patients with acute on chronic liver failure display sepsis-like immune paralysis. J. Hepatol. 42, 195-201 (2005
182. Leon C. G., Tory R., Jia J., Sivak O. & Wasan K. M. Discovery and development of toll like receptor 4 (TLR4) antagonists: a new paradigm for treating sepsis and other diseases. Pharm. Res. 25, 1751-1761 (2008
183. Imperiale T. F. & McCullough A. J. Do corticosteroids reduce mortality from alcoholic hepatitis?. A meta-analysis of the randomized trials. Ann. Intern. Med. 113, 299-307 (1990
184. Maddrey W. C., et al. Corticosteroid therapy of alcoholic hepatitis. Gastroenterology 75, 193-199 (1978
185. Hardy T., et al. White cell count and platelet count associate with histological alcoholic hepatitis in jaundiced harmful drinkers. BMC Gastroenterol. 13, 55. (2013
186. Mookerjee R. P., et al. The role of liver biopsy in the diagnosis and prognosis of patients with acute deterioration of alcoholic cirrhosis. J. Hepatol. 55, 1103-1111 (2011
187. US National Library of Medicine Clinical.Trials.gov [online], https://Clinical.Trials.gov/ct2/show/NCT01912404 (2015
188. US National Library of Medicine Clinical.Trials.gov [online], https://Clinical.Trials.gov/ct2/show/NCT02161653 (2014
189. US National Library of Medicine Clinical.Trials.gov [online], https://Clinical.Trials.gov/ct2/show/NCT02019056 (2013
190. US National Library of Medicine Clinical.Trials.gov [online], https://Clinical.Trials.gov/ct2/show/NCT01809132 (2014
191. US National Library of Medicine Clinical.Trials.gov [online], https://Clinical.Trials.gov/ct2/show/NCT02281929 (2014
192. US National Library of Medicine Clinical.Trials.gov [online], https://Clinical.Trials.gov/ct2/show/NCT02116556 (2014
193. US National Library of Medicine Clinical.Trials.gov [online], https://Clinical.Trials.gov/ct2/show/NCT02326103 (2014
194. US National Library of Medicine Clinical.Trials.gov [online], https://Clinical.Trials.gov/ct2/show/NCT01922895 (2014
195. US National Library of Medicine Clinical.Trials.gov [online], https://Clinical.Trials.gov/ct2/show/NCT01820208 (2013
196. US National Library of Medicine Clinical.Trials.gov [online], https://Clinical.Trials.gov/ct2/show/NCT02039219 (2014
197. US National Library of Medicine Clinical.Trials.gov [online], https://Clinical.Trials.gov/ct2/show/NCT01903798 (2013
198. US National Library of Medicine Clinical.Trials.gov [online], https://Clinical.Trials.gov/ct2/show/NCT02072746 (2014
199. US National Library of Medicine Clinical.Trials.gov [online], https://Clinical.Trials.gov/ct2/show/NCT01875081 (2014
200. US Department of Health and Human Services. NIH Research Portfolio Online Report Tools (RePORT) [online], http://projectreporter.nih.gov/Reporter-Viewsh.cfm?sl=13EBC0034F84C1DE7598B8961CAA4A01A2FFCEB861BF (2015